Central Nervous System Tumor, Pediatric Clinical Trial
Official title:
INI1 Mutation Analysis and Expression Profiling of Embryonal CNS Tumors
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the
development of some types of cancer.
PURPOSE: Genetic study to understand how genes may be involved in the development of brain
tumors in young children.
OBJECTIVES:
- Determine the frequency and type of deletions and mutations of the INI1 gene in infants
with embryonal central nervous system tumors.
- Compare the gene expression profiles in infants with atypical teratoid/rhabdoid tumors
vs medulloblastoma or primitive neuroectodermal tumor.
OUTLINE: This is a multicenter study.
Tumor samples are analyzed by fluorescence in situ hybridization (FISH) for deletions of
INI1 gene in chromosome band 22q11.2. Tumors without demonstration of deletions of INI1 gene
by FISH are examined by polymerase chain reaction (PCR)-based microsatellite analysis for
loss of heterozygosity using markers that map to 22q11.2.
DNA from tumor tissue is analyzed for mutations in the exons of the INI1 gene. Isolated
matched normal DNA may be analyzed for identification of germline mutations. Parental DNA
may be analyzed to identify inherited germline mutations of the INI1 gene.
The patient's physician may receive the results of the genetic testing. The results do not
influence the type or duration of treatment.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 25 months.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00098865 -
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
|
Phase 2 | |
| Completed |
NCT01346267 -
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT03638167 -
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03500991 -
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
|
Phase 1 | |
| Terminated |
NCT01348607 -
Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
|
Phase 2 | |
| Completed |
NCT00357500 -
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
|
Phase 2 | |
| Recruiting |
NCT05672043 -
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
|
||
| Not yet recruiting |
NCT02050243 -
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00084838 -
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
|
Phase 2 |